Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$745.72
-1.2%
$795.44
$677.09
$972.53
$706.75B0.483.59 million shs3.87 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$68.17
+1.7%
$67.00
$57.00
$148.15
$305.91B0.656.61 million shs12.55 million shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$2.08
+5.3%
$1.85
$1.14
$12.60
$64.27M1.74360,965 shs164 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.22%-0.02%-11.40%-13.96%-4.82%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.81%+4.27%+17.56%-18.24%-48.72%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-8.37%+1.55%+37.28%-38.24%-83.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9796 of 5 stars
4.43.03.34.03.92.51.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.7239 of 5 stars
4.23.02.50.03.10.04.4
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1.1467 of 5 stars
3.51.00.00.01.90.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.80
Moderate Buy$1,011.3735.62% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.38
Hold$135.0098.03% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
3.00
Buy$16.60700.00% Upside

Current Analyst Ratings Breakdown

Latest NVO, LLY, and SKYE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/2/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,100.00 ➝ $1,050.00
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Reduce$1,150.00 ➝ $700.00
4/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Moderate Sell
4/28/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/25/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Dbs Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSell
4/22/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$975.00
4/17/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$49.00B14.42$12.16 per share61.34$15.05 per share49.55
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$303.14B1.01$3.16 per share21.57$4.64 per share14.69
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A($0.17) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$12.2963.6823.961.4023.51%85.24%16.19%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.3820.7214.630.9034.81%84.68%26.29%8/6/2025 (Estimated)
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$37.65M-$0.82N/AN/AN/AN/A-45.78%-37.44%N/A

Latest NVO, LLY, and SKYE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.31-$0.28+$0.03-$0.28N/AN/A
5/7/2025Q1 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.92$0.92N/A$0.92N/A$11.87 billion
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64$3.34-$1.30$3.06$12.77 billion$12.73 billion
3/20/2025Q4 2024
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.30-$0.24+$0.06-$0.24N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.80%+15.21%48.82%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.632.39%+25.26%48.22%N/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A

Latest NVO, LLY, and SKYE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.73%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
14.19
14.19

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
3.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000947.74 million948.08 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1130.98 million29.43 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$745.72 -9.39 (-1.24%)
Closing price 05/20/2025 03:58 PM Eastern
Extended Trading
$745.60 -0.12 (-0.02%)
As of 09:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$68.17 +1.15 (+1.72%)
Closing price 05/20/2025 03:58 PM Eastern
Extended Trading
$68.62 +0.45 (+0.66%)
As of 09:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$2.08 +0.11 (+5.33%)
Closing price 08:42 AM Eastern
Extended Trading
$2.07 -0.01 (-0.24%)
As of 09:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.